New bladder cancer drug tested before surgery: a safety first step
NCT ID NCT05055050
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 29 times
Summary
This early-phase study tests the safety of a drug called UGN-201 in 10 people with bladder cancer who are scheduled to have their bladder removed (cystectomy). The drug is given before surgery to see if it is safe and to explore whether it can shrink the tumor. Researchers also look at immune system changes in blood, urine, and tumor tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.